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Altered Expression of the Transcription Factor Mef2c
during Retinal Degeneration in Rpe65–/– Mice
Pascal Escher,1,2 Daniel F. Schorderet,1,2,3 and Sandra Cottet1,2
PURPOSE. To investigate the role of the myocyte enhancer
factor 2 (Mef2) transcription factor family in retinal diseases,
Mef2c expression was assessed during retinal degeneration in
the Rpe65–/– mouse model of Leber’s congenital amaurosis
(LCA). Mef2c-dependent expression of photoreceptor-specific
genes was further addressed.
METHODS. Expression of Mef2 members was analyzed by oli-
gonucleotide microarray, quantitative PCR (qPCR), and in situ
hybridization. Mef2c-dependent transcriptional activity was as-
sayed by luciferase assay in HEK293T cells.
RESULTS. Mef2c was the only Mef2 member markedly down-
regulated during retinal degeneration in Rpe65–/– mice. Mef2c
mRNA level was decreased by more than 2-fold at 2 and 4
months and by 3.5-fold at 6 months in retinas of Rpe65–/– mice.
Downregulation of Mef2c at the protein level was confirmed in
Rpe65–/– retinas. The decrease in Mef2c mRNA levels in the
developing Rpe65–/– retinas from postnatal day (P) 13 onward
was concomitant with the decreased expression of the rod-
specific transcription factors Nrl and Nr2e3. Nrl was further
shown to drive Mef2c transcriptional activity, supporting a
physiological role for Mef2c in the retina. In addition, Mef2c
appeared to act as a transcriptional repressor of its own ex-
pression and the expression of the retina-specific retinal G-pro-
tein coupled receptor (Rgr), rhodopsin, and M-opsin genes.
CONCLUSIONS. These findings highlight the early altered regu-
lation of the rod-specific transcriptional network in Rpe65-
related disease. They also indicate that Mef2c may act as a
novel transcription factor involved in the development and the
maintenance of photoreceptor cells. (Invest Ophthalmol Vis
Sci. 2011;52:5933–5940) DOI:10.1167/iovs.10-6978
Mutations in the gene encoding the RPE-specific protein 65kDa (RPE65) account for approximately 10% of cases of
Leber’s congenital amaurosis (LCA).1 The hallmarks of LCA
pathogenesis are early and severe rod–cone dystrophy.2 Af-
fected patients experience the degeneration of photoreceptor
cells associated with congenital nystagmus, profound visual
deficiency, night blindness, and reduced or nondetectable
ERG.
The iron (II)-dependent isomerohydrolase RPE65 directs
the synthesis of the 11-cis retinol necessary for light-induced
phototransduction mediated by rod and cone opsins.3–5
Rpe65–/– mice exhibit defects in retinal morphology, function,
and biochemistry resembling those seen in human LCA.6,7 In
the absence of RPE65, all-trans-retinyl esters accumulate in
lipid droplets within the RPE, reflecting defects in the visual
cycle in these cells.6 Rpe65–/– mice lack the 11-cis retinal
chromophore, do not generate adequate levels of visual pig-
ment, and have severely depressed light- and dark-adapted ERG
responses.6–8 Unliganded rod opsin triggers light-independent,
constitutive activation of residual phototransduction cascade
leading to photoreceptor cell death9 through a Bax-related
pathway.10
The myocyte enhancer factor 2 (Mef2) family of transcription
factors comprises four gene products in mammals, Mef2a-d.11
Mef2 proteins (Mef2s) function as central regulators of diverse
developmental programs controlling cell differentiation and
organogenesis, and are especially involved in muscle and neu-
ronal differentiation (reviewed by Potthoff and Olson12). Mef2s
contain in the n terminus the MADS (MCM1-agamous-deficiens-
serum response factor)-box and the Mef2 domain responsible
for DNA binding, dimerization, and cofactor recruitment.
These two regions are highly conserved, with around 95%
amino acid similarity among the vertebrate Mef2 factors. The C
terminus of Mef2s contains an evolutionarily divergent tran-
scriptional activation domain subjected to a complex pattern
of alternative splicing.11,12 Mef2 homo- or heterodimers bind
to the consensus DNA regulatory sequence (C/Y)TA(A/
T)4TA(G/R).
11,13 The transcriptional activity of Mef2s is stimu-
lated by mitogen-activated protein kinase signaling.12 Calcium-
dependent signals also activate Mef2s by stimulating calcium-
dependent kinases that phosphorylate class II histone
deacetylases, thereby promoting their dissociation from Mef2
and derepressing Mef2 target genes. In addition, Mef2s recruit
numerous cofactors to drive specific cell differentiation.
Mef2s were originally described as muscle-enriched tran-
scription factors in differentiated myotubes and were recog-
nized as key regulators of cardiac myogenesis and morphogen-
esis.11 For instance, mice with a targeted disruption of Mef2c
(Mef2c–/– mice) died early during embryonic development
because the heart tube did not undergo looping morphogene-
sis and the right ventricle did not form.14 During skeletal
muscle development, Mef2s cooperate and strongly potentiate
the transcriptional activity of the myogenic basic helix-loop-
helix (bHLH) proteins MyoD, Myf5, myogenin, and MRF4.11 In
vertebrates, the myogenic bHLH transcription factors directly
activate Mef2c expression by binding to a skeletal muscle-
specific enhancer located immediately upstream of the first
untranslated exon of mouse Mef2c, which in mice is 71 kb
upstream of the first translated exon.15,16 In addition to striated
muscles, Mef2s are highly expressed in several brain re-
gions.17–19 In this organ, time-regulated expression of Mef2
proteins is consistent with their role in neuronal differentiation
and maintenance (reviewed by Heidenreich and Linseman20).
Mef2c is robustly expressed by cortical neurons and repre-
sents the predominant Mef2 member in the cerebral cortex.21
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Embryonic conditional knock-out of Mef2c in nestin-express-
ing neural stem/progenitor cells resulted in impaired differen-
tiation of postmitotic neurons associated with neuronal defects
and severe behavioral deficits.22 These data further supported
a crucial role of Mef2c in the neocortex with respect to neuron
development, distribution, and electrical activity.19,21,23 Fi-
nally, human MEF2C haploinsufficiency caused by a small de-
letion within the MEF2C gene has been associated with severe
mental retardation and cerebral malformation.24–27
The observation that Mef2c levels were decreased at the
transcriptional level in several models of retinal degenera-
tion—the Rpe65–/–,28 the Rho–/–,29 the Crx–/–,30 and the
Nrl–/– 31 mouse—prompted us to further investigate Mef2c in
the retina.
METHODS
Mouse Lines and Genotyping
These studies adhered to the ARVO statement for the use of animals in
ophthalmic and vision research and were approved by the Veterinary
Service of the State of Valais (Switzerland). Wild-type C57BL/6 mice
(WT) were purchased from Charles River Laboratories (Les Oncins,
France). Rpe65–/– mice are on a C57BL/6 genetic background (from T.
Michael Redmond, National Institutes of Health, Bethesda, MD). The
genotype of the mice was determined by PCR analysis with genomic
DNA isolated from tail tissue. Animals were kept in a 12-hour light/dark
cycle with unlimited access to food and water.
Tissue Isolation and RNA Extraction
Age-matched animals were killed by cervical dislocation. Retinas from
each mouse strain were quickly isolated in RNA stabilization reagent
(RNAlater; Ambion, Huntingdon, UK) before being transferred in total
RNA isolation reagent (TRIzol; Invitrogen, Basel, Switzerland) and
stored at –80°C until RNA extraction. Total RNA was extracted accord-
ing to manufacturer’s instructions, and the amount of total RNA was
determined by a quantitation assay (RiboGreen; Invitrogen).
Oligonucleotide Microarray
Oligonucleotide microarray was previously described in detail.28
Briefly, 1 g of total RNA was used to generate double-stranded cDNA
used as a template for biotinylated cRNA synthesis using a commer-
cially available kit (Affymetrix GeneChip Expression 3-Amplification
Kit for IVT Labeling Kit; Affymetrix, Santa Clara, CA). Next, 20 g of
target cRNA were fragmented and hybridized on an array (Affymetrix
Mouse Genome 430 2.0 GeneChips; Affymetrix), and washed chips
were scanned on a scanner (Affymetrix GeneChip Scanner 3000 using
GCOS software; Affymetrix). Data normalization was performed using
the Robust Multi-Array Analysis algorithm (RMA) as implemented in
specific commercially available software (GeneSpring, version 7.2;
Agilent Technologies, Waldbronn, Germany). Three mice were used
for each condition studied.
Quantitative PCR Analysis
The equivalent of 50 ng of total RNA was used for PCR amplification
using a PCR reagent (2 brilliant SYBR Green QPCR Master Mix;
Agilent) with either 125 nM (Mef2a, Mef2d, Nr2e3, and Nrl), 250 nM
(Mef2b or Mef2c), or 400 nM (Rl8) forward and reverse primer
pairs. Real-time PCR was performed in triplicate in a PCR system
(Mx3000P; Agilent) with the following cycling conditions: 40 cycles of
denaturation at 95°C for 30 seconds, annealing at 55°C (except for
Mef2b at 65°C) for 30 seconds, and extension at 72°C for 60 seconds.
Quantitative values were obtained by the cycle number (Ct value)
reflecting the point at which fluorescence starts to increase above
background at a fixed threshold level. Values obtained for the target
genes were normalized with the housekeeping ribosomal protein L8
(Rl8) gene. Three to four mouse retinas were used for each condition
studied. Primer sequences are shown in Table 1.
In Situ Hybridization
Eyes were enucleated and fixed for 30 minutes in ice cold 4% parafor-
maldehyde (PFA)/1 PBS-diethylpyrocarbonate (DEPC) and then trans-
ferred to a 30% sucrose/H2O-DEPC solution overnight at 4°C. Fixed and
cryopreserved eyes were embedded in Yazzulla (30% albumin/3%
gelatin in PBS-DEPC) and cut into 10-m thick cryosections using a
cryostat (CM1900; Leica Microsystems, Heerbrugg, Switzerland). Eye
sections were thawed and mounted on reagent (Vectabond; Vector
Laboratories, Burlingame, VT)-treated glass slides (SuperFrost Plus;
Menzel Gla¨ser, Braunschweig, Germany). PCR amplified Mef2c cDNA
fragment (nucleotides 406 to 810 from the mouse Mef2c coding se-
quence) was subcloned into a vector (pGEM-T Easy Vector; Promega,
Madison, WI) according to the manufacturer’s protocol. Blast analysis
of the sequence used for generating the Mef2c probe showed no
similarity with the other Mef2 genes. Plasmids were linearized with
SpeI and ApaI restriction enzymes to obtain a template sequence for
either the sense or antisense RNA probes. Digoxygenin (DIG)-labeled
antisense and sense cRNA probes were synthesized by in vitro tran-
scription of 1 g of linearized DNA with either T7 or Sp6 RNA
polymerases (DIG RNA labeling mix; Roche, Rotkreuz, Switzerland)
according to the manufacturer’s protocol. DIG-labeled sense and anti-
sense probes were tested by immunodot blotting and equal amounts of
probe (1/100 dilution) were used in the experiment. In situ hybridiza-
tions were performed at a hybridization temperature of 48°C as pre-
viously described.32 Slides were then washed twice in 0.1 SSC at
65°C for 30 minutes and then incubated for 2 hours at room temper-
ature (RT) with anti-DIG antibodies alkaline phosphatase (AP) conju-
gated (Roche) diluted at 1/5,000. Color staining was developed by
overnight incubation with NBT/BCIP (Roche) in the dark at RT. The
reaction was stopped by adding TE (1/10), followed by a final wash in
95% EtOH for 45 minutes Eyes from three mice were analyzed for each
genotype.
Subcellular Fractionation
Cytosolic and nuclear fractions were prepared from adult WT and
Rpe65–/– retinas using extraction reagents (NE-PER Nuclear and Cyto-
plasmic Extraction Reagents; Thermo Fisher Scientific, Lausanne, Swit-
TABLE 1. Primer Sequences for Real-Time PCR Analysis
Gene Forward Primer (5-3) Reverse Primer (5-3)
GenBank
Accession Number
Mef2a AGCAGCACCATCTAGGACAA CTGCTGTTGGAAGCCTGATG U30823
Mef2b GCAACGCCTCTTCCAGTATG AGTGTCCTCAGCAGCTTCTC D50311
Mef2c AGATCTGACATCCGGTGCAG TCTTGTTCAGGTTACCAGGT NM_025282
Mef2d CAGCAGCCACCTCAGCAACA CCAAGTATCCAGCCGCATCC NM_133665
Nr2e3 TGCAGAATGAGCGCCAACCT TGAAGAGCAGGCGAGCAGAT NM_013708
Nrl TGTCTGTGCGCGAGTTGAAC AAGAGGTGTGTGTGGTCGTC NM_008736
Rl8 ACTGGACAGTTCGTGTACTG GCTTCACTCGAGTCTTCTTG NM_012053
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zerland) according to the manufacturer’s instructions. Protein amounts
in cytosolic and nuclear fractions were determined using the micro
BCA protein assay (Thermo Fisher Scientific). Three mouse retinas
were used for each condition studied.
Western Blot Analysis
Equal amounts of proteins, as determined by the microBCA protein
assay (Thermo Fisher Scientific), were resolved on 10% SDS-PAGE gels
followed by transfer on PVDF membrane (Whatman/Schleicher &
Schuell, Sanford, UK). Membranes were blocked in 5% nonfat dried
milk before being immunoassayed using rabbit antibodies against
Mef2c (diluted 1/400; Aviva Systems Biology, San Diego, CA) and high
mobility group protein B1 (HMGB1; diluted 1/5,000; Abcam, Cam-
bridge, UK), and a mouse antibody against tubulin (1/40,000; Sigma,
Buchs, Switzerland). Mef2c blocking peptide (Aviva Systems Biology),
used as immunogen to generate the Mef2c antibody, was used to assess
the specificity of Mef2c immunoblotting. Briefly, primary Mef2c anti-
body was preadsorbed with a fivefold excess (weight) of blocking
peptide in 500 L of blocking buffer before to be used in Western blot
analysis.
Cloning and Plasmids
A 1311-bp fragment spanning from 1141 to 170 of the mouse
Mef2c gene was amplified with primers mMef2cpfor (5-GGGGTAC-
CGATACTGGGTGATGCCATTC-3) and mMef2cprev (5-CGGGATC-
CGCTTCTCCAGGAAGTTGTTC-3) and subcloned into the KpnI/BglII
sites of the pGL2-promoter (pGL2-prom) luciferase reporter vector
(Promega). This region contains the previously described myocyte-
specific enhancer and most of the first untranslated exon15 (see Fig. 7).
5-promoter deletion constructs were amplified with forward pri-
mers mMef2cp-780for (5-GGGGTACCCTTCCAACTGAATTTACTTA-3),
mMef2cp-714for (5-CGGGGTACCTGTCCTTACCTTAACCAGTC-3),
mMef2cp-418for (5-GGGGTACCCAGTTTAATAACCTGAAATG-3),
respectively, and mMef2cprev. A KpnI-XbaI fragment spanning region
1141/843 was subcloned into a synthesis kit (pBluescriptII, pBSII;
Stratagene, La Jolla, CA) and then transferred into the KpnI/SacI sites
of pGL2-prom. A XbaI/HindIII fragment spanning region -843/-546
was subcloned into pBSII, excised with KpnI/BamHI and subcloned
into the KpnI/BglII sites of pGL2-prom. We cloned a 1171-bp fragment
of the proximal promoter of the mouse Rgr (retinal G protein coupled
receptor) gene, amplified with primers mRgrpfor (5-GGGGTACCG-
GCATTGTTACAATTCCACC-3) and mRgrprev (5-CGGGATC-
CAGCTCTTTTCTGGCTCTCTG-3) into the KpnI/BglII sites of the
pGL2-prom. All constructs were verified by sequencing on a gene
analyzer (ABI 3130xl Genetic Analyzer using the Big Dye Terminator
Labeling Kit; Applied Biosystems, Carlsbad, CA). In addition, we used
as luciferase reporter constructs a 225-bp fragment of the bovine
rhodopsin proximal promoter (BR225-Luc) and a 250-bp fragment of
the mouse M-opsin proximal promoter (Mop250-Luc).33 The different
expression vectors for mouse (m) Mef2c were pcDNA3.1-mMEF2C,
pcDNA3.1-mMEF2C-VP16, where amino acids 1 to 143 were fused to
the VP16 transcriptional activation domain, and the DNA-binding de-
ficient dominant-negative pcDNA3.1-mMEF2C(p.R3T), bearing a muta-
tion in the highly conserved N-terminal MADS-box.34 Finally, the pre-
viously described expression vectors for human (h) CRX (cone-rod
homeobox), pcDNA3.1/HisC-hCRX, and for human NRL (neural retina
leucine zipper), pMT-hNRL, were used.33
Cell Culture and Luciferase Assays
For transactivation assays, human embryonic kidney (HEK) 293T cells
were grown at 37°C and 5% CO2 in Dulbecco’s modified Eagle’s
medium (DMEM; PAA Laboratories GmbH, Pasching, Austria) supple-
mented with 10% FCS, 100 U/mL penicillin and 100 g/mL streptomy-
cin (Invitrogen). Cells were plated in 12-well plates (TPP, Trasadingen,
Switzerland) and transfected at a confluence of 30% with the calcium
phosphate method (ProFection; Promega). Per well, 30 ng of each of
the expression vectors and 500 ng of luciferase reporter constructs
were used. As internal standard, 33 ng of plasmid CMV (Clontech,
Moutain View, CA) encoding -galactosidase were used. To keep the
total transfected DNA quantity constant, appropriate quantities of
pcDNA3.1/HisC empty vector were added in all experiments. All
plasmids were prepared on columns (NucleoBond PC500; Macherey-
Nagel, Du¨ren, Germany). Enzymatic activities were assessed with an
assay system (Luciferase Assay System; Promega) and standard -Gal
assay. Two to four independent experiments were performed in trip-
licate (n  6–12).
In Silico Promoter Analysis
Prediction for transcription factor binding sites was achieved both
manually for A/T-rich sequences and with AliBaba 2.1, Match 1.0, and
Patch 1.0 software (available at http://www.gene-regulation.com for
c-Jun, c-Fos, c-Maf, Crx, and Pax response elements).
FIGURE 1. Transcriptional downregulation of Mef2c in Rpe65–/– ret-
inas. mRNA expression from wild-type (wt, black diamond) and
Rpe65–/– retinas (ko, gray square) was assessed at 2, 4, and 6 months
of age (2–6m) by oligonucleotide microarray (left panels) and vali-
dated by quantitative PCR (right panels). Relative mRNA levels were
expressed as fold inductions relative to samples from 2-month-old wt
mice arbitrarily set to 1. Mef2c was the only Mef2 member markedly
downregulated in diseased retinas at all ages, while expression of the
other Mef2 members remained essentially unchanged in microarray
and qPCR analyses. Data are the mean  SEM of three (left panels) and
three to four (right panels) independent experiments. *P  0.01 by
ANOVA test for Mef2c expression levels in Rpe65–/– versus wt.
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Statistical Analysis
Statistical analysis was performed with commercially available software
(Prism 4.0.2; GraphPad Software Inc., La Jolla, CA). All results were
expressed as mean  SEM of the indicated number of experiments.
RESULTS
Downregulated Mef2c mRNA and Protein
Expression in Rpe65–/– Mice
In an initial gene expression profiling study, we observed that
130 known genes were downregulated in Rpe65–/– mice dur-
ing disease progression.28 In this study, we investigated the
retinal expression of Mef2 transcription factor members in 2-,
4-, and 6-month-old WT and Rpe65–/– mice by oligonucleotide
microarray and qPCR analyses. In the microarray study, Mef2c
was the only member showing altered expression in Rpe65–/–
retinas when compared to WT retinas. A 50% decrease in
Mef2c mRNA level was observed at all ages during disease
progression, whereas Mef2a, -b, and -d mRNA expression re-
mained unchanged (Fig. 1, left panels). QPCR confirmed the
decreased level of Mef2c mRNA in Rpe65–/– retinas compared
to WT levels (Fig. 1, right panels).
The intracellular localization of Mef2c in retinal cells was
further investigated by Western blot analysis in adult WT and
Rpe65–/– retinas. After subcellular fractionation of retinal cell
extracts, cytosolic and nuclear-enriched fractions were immu-
noassayed using a Mef2c antibody. The protein was detected in
the cytosol and the nucleus of the retinal cells (Fig. 2A) and
reduction of Mef2c at the protein level was confirmed in
Rpe65–/– retinas (Fig. 2B). High mobility group protein B1
(HMGB1; P63158, www. uniprot.org) was used as a nuclear
marker to assess the quality of the nuclear-enriched fractions.
The specificity of Mef2c immunoblotting was further con-
firmed by preadsorbing Mef2c antibody with a blocking pep-
tide used as immunogen to generate the antibody (Fig. 2C).
Expression of Mef2c mRNA in Adult WT Retinas
Although transcriptome analysis in rod-deficient Rho–/–, Nrl–/–,
and Crx–/– mice indirectly indicated that Mef2c might be a
rod-enriched transcription factor,29–31 its expression in the
retina has not yet been addressed.
We assessed Mef2c mRNA expression in 2-month-old WT
retinas by in situ hybridization with antisense (Fig. 3A) and
sense probes (Fig. 3B). Mef2c was expressed in the inner
nuclear layer (INL), outer nuclear layer (ONL), and inner seg-
ments (IS) of the photoreceptors. Higher magnification of the
antisense-probed retina section (Fig. 3E) revealed Mef2c mRNA
expression in the cellular bodies and IS compartments of the
photoreceptors. Mef2c is highly expressed in striated muscles;
its expression in ocular muscle tissue hybridized with anti-
sense (Fig. 3C) and sense (Fig. 3D) probes confirmed the
specificity of the probe.
Early Altered Regulation of Nrl, Nr2e3 and Mef2c
Transcriptional Factors in Rpe65–/– Mice
In the microarray analysis, we observed that the expression of
Nrl and Nr2e3 was downregulated in Rpe65–/– retinas at 2 to 6
months of age (Fig. 4). We addressed the question whether the
expression of the rod-specific transcription factors and Mef2c
might be altered during early postnatal (P) retinal development
from P7 to P13. As shown by qPCR analysis (Fig. 5), the
expression of Nrl, Nr2e3, and Mef2c was significantly de-
creased in Rpe65–/– retinas from P13 onwards, at a time when
photoreceptors are terminally differentiated. These observa-
tions demonstrate that the regulation of the rod-specific tran-
scriptional network, along with Mef2c, is altered early in the
newly differentiated retinas of Rpe65–/– mice.
Mef2c Acts as a Transcriptional Repressor in
HEK293T Cells
Nrl interacts with Crx and Nr2e3 and regulates, either alone or
synergistically, the expression of cone opsins35,36 and several
rod-specific genes, including rhodopsin35–37 and rod cGMP-
phosphodiesterase.38,39
We addressed the question whether Mef2c might regulate
the expression of photoreceptor-specific genes, possibly in
conjunction with other known rod-enriched transcription fac-
tors. We first tested the transcriptional activity of Mef2c on a
FIGURE 2. Western blot analysis of
Mef2c protein in Rpe65–/– retinas. After
subcellular fractionation of retinal cell
extracts from adult wt andRpe65–/– (ko)
mice, 50 g of total proteins were
loaded in 10% SDS-PAGE and immunoas-
sayed using antibodies against Mef2c and
the nuclear marker HMGB1. (A) Mef2c
protein was detected in the cytosol and
nucleus of retinal cells. The decreased
expression of Mef2c at the protein level
was confirmed in Rpe65–/– retinas. (B)
After densitometric analyses of Mef2c
and tubulin immunoblots, tubulin-nor-
malized Mef2c was expressed as fold
change relative to wt retinas. Data are
the mean  SEM of three independent
experiments. (C) Specificity of Mef2c
immunoblotting was further confirmed
by preadsorbing Mef2c antibody with a
specific blocking peptide.
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1141/170 Mef2c promoter region encompassing the previ-
ously described myocyte-specific enhancer, located upstream
of the first untranslated exon of the mouse Mef2c gene.15 The
429 base pairs immediately located upstream of the transcrip-
tion initiation site are evolutionarily-conserved among verte-
brates, and Mef2c was unable to bind to A/T-rich sequences
located in this region, even in presence of myogenins binding
to a conserved E-box located at 67/72.15 Mef2c repressed
the activity of this myocyte-specific enhancer construct by
60% (Fig. 6A). Repression was relieved in presence of the
dominant-negative Mef2c, indicating that the repressor activity
of Mef2c was partially DNA-binding dependent. As a positive
control, we used a constitutively active Mef2c fused to the
VP16 activator domain, which resulted in increased transcrip-
tional activity of the Mef2c promoter. We then tested whether
photoreceptor-specific transcription factors would be able to
regulate this promoter region (Fig. 6B). NRL increased the
activity of the Mef2c promoter by approximately 2.5-fold,
whereas CRX did not. Interestingly, Mef2c acted as a repressor
in presence of NRL and/or CRX. This Mef2c repressor activity
was also observed on the retina-specific RGR promoter, the
rod-specific rhodopsin promoter, and the cone-specific M-op-
sin promoter.
NRL Stimulates Mef2c Promoter Activity
To identify promoter regions mediating the regulation of Mef2c
by Mef2c and NRL, we analyzed the sequence for potential
transcription factor binding sites. We were unable to identify
reported Nrl response element (NRE) sequences, such as an
extended activator protein (AP)-1 binding site present in the
rhodopsin promoter (TGCTGATTCCAGCC), or nonclassical
binding sites present in the Nr2e3 (GCTGAGT/AAAG) and
Ppp2r5c (protein phosphatase 2A regulatory subunit) (GGC-
CAATCAGC) promoters.37,40,41 We noticed a repetition of
three A/T-rich sequences at locations 758/749 (CTA-
AAAAAGA), 743/734 (CTAAAAATTC), and 729/720
(CTAATAAATG). In silico analysis identified a c-Maf binding
site at 206/200 (ATTTTCC) and, of note for retinal devel-
opment, potential CRX, PAX6, and PAX2 response elements
(Fig. 7A).
We generated a number of deletions of the Mef2c proximal
promoter to evaluate the activity of the different transcription
FIGURE 3. Localized expression of
Mef2c in retinal cell layers. In situ
hybridization studies were per-
formed on retina sections from
2-month-old wt mice with antisense
(A) and control sense (B) probes.
Mef2c mRNA was detected in INL,
ONL, and photoreceptor IS. As a
control of the specificity of the
probe, Mef2c transcript was ob-
served in ocular muscle tissue hy-
bridized with antisense probe (C)
but not with sense probe (D). Higher
magnification (E) of the antisense-
probed retina section reveals Mef2c
expression in the cellular bodies and
the IS compartments of the photore-
ceptors. GCL, ganglion cell layer;
INL, inner nuclear layer; IS, inner seg-
ments; ONL, outer nuclear layer; OS,
outer segments.
FIGURE 4. Downregulated expres-
sion of rod-specific transcription fac-
tors during progression of the dis-
ease in Rpe65–/– mice. Microarray
analysis in wt (black diamond) and
Rpe65–/– (ko, gray square) mice at
2, 4, and 6 months of age (2–6m)
revealed that Nrl and Nr2e3 expres-
sion was decreased in diseased reti-
nas relative to wt retinas. Data are
the mean  SEM of three indepen-
dent experiments. *P  0.01 by
ANOVA test for Nrl and Nr2e3 ex-
pression levels in Rpe65–/– versus
wt, except for Nr2e3 at 4 months of
age.
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factors (Fig. 7B). The longest fragment (1141/170) showed
the highest activity (Fig. 7C), and NRL induced the promoter
activity by 2.5-fold. Whereas the activity of the -1141/-843 was
at the limit of detection, the promoter construct encompassing
region843/546 was induced 3.3-fold by NRL. Activation by
NRL was 2.3-fold with the 780/170 construct, but reduced
to 1.4- and 1.9-fold with the 714/170 and 418/170
constructs. Mef2c acted as a repressor on all promoter deletion
constructs. Despite the in silico prediction of two CRX re-
sponse elements, CRX was unable to activate any of the pro-
moter constructs.
DISCUSSION
In the present study, we reported the expression of the Mef2
family of transcription factors in the retina. Among them,
Mef2c was the only member showing marked downregulation
at transcript and protein levels during disease progression in
Rpe65–/– mice. In situ hybridization analysis revealed that ret-
inal expression of Mef2c was restricted to the interneurons of
the INL and to the cellular bodies and inner segments of the
photoreceptors. Crx, Nrl, and Nr2e3 showed a photoreceptor-
restricted expression, with their RNAs being also present in the
inner segments.42–44 IS-specific enriched RNA is a common
pattern among the rod-enriched transcription factors and other
photoreceptor-enriched genes, although the functional signifi-
cance of this remains unclear. These data indicate that Mef2c
displayed a similar expression pattern in the retina because it
was observed for the rod-enriched transcriptional regulators
directing photoreceptor development.
In this study, we reported altered expression of Mef2c early
in the newly differentiated Rpe65–/– retinas, which was con-
comitant with the decreased expression of Nrl and Nr2e3. In
the initial microarray experiment, 213 genes were also down-
regulated in Rpe65-deficient retinas.28 Several transcriptional
regulators were present among these, including HIF1 (hyp-
oxia inducible factor 1, alpha subunit), Pbx1 (pre B-cell leuke-
mia transcription factor 1), PPAR (peroxisome proliferator-
activated receptor alpha). Their potential interaction with
Mef2c, or involvement in Mef2c-dependent pathways, remains
to be determined. Mef2c retinal expression has been shown to
be almost completely abolished in Crx–/–,30 Nrl –/–,30,31 and
Rho–/– 29 mice, suggesting that Mef2c may be a rod-enriched
transcription factor. Moreover, Mef2c was identified as a puta-
tive direct target of the rod-specific Nrl transcription factor,
indicating that Mef2c may be involved in the transcriptional
network directing photoreceptor differentiation and mainte-
nance.31 In addition, we observed in healthy retina that Mef2c
transcriptional expression, similarly to what is known for Nrl
FIGURE 5. Early downregulation of photoreceptor-enriched transcription factors in Rpe65–/– mice. qPCR analysis of the expression of Nrl, Nr2e3,
and Mef2c during postnatal retinal development in wt (black diamond) and Rpe65–/– (ko; gray square) mice at P7, P10, and P13 expressed as
fold change relative to wt at P7. Impaired expression of the three transcription factors was observed from P13 onwards in Rpe65–/– retinas. Data
are the mean  SEM of four independent experiments. *P  0.005 by t-test for transcript expression levels at P13 in Rpe65–/– versus wt.
FIGURE 6. Transcriptional regulation by Mef2c in HEK293T cells. (A)
Mef2c acts as a repressor on the Mef2c myocyte–specific enhancer.
Expression vectors for mouse wt Mef2c (MEF2C), a dominant-negative
Mef2c (MEF2C_DN), and a constitutively active Mef2c (MEF2C_CA)
were cotransfected with the mouse Mef2c luciferase reporter con-
struct. (B) Mef2c acts as a repressor toward the photoreceptor-specific
transcription factors NRL and CRX. Combinations of mouse MEF2C
(M), human NRL (N), and human CRX (C) expression vectors were
cotransfected with Mef2c, RGR, rhodopsin, or M-opsin luciferase re-
porter constructs. Three independent experiments were performed in
triplicate (n  9) and results are shown as mean  SEM. Firefly
luciferase activities were normalized to -galactosidase activities and
presented as fold-inductions relative to the respective promoter con-
struct cotransfected with the empty pcDNA3.1 expression vector.
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and rod-specific genes, increased during maturation of the
photoreceptors from P13 to P30.
In our heterologous transactivation assay in 293T cells, NRL
alone was able to activate Mef2c expression. NRL is essential
for rod development,45 and Mef2c might therefore be impor-
tant for the development and maintenance of fully functional
rods. Notably, CRX, a master regulator of photoreceptor devel-
opment,42 was unable to activate Mef2c expression. This sug-
gested that Mef2c might function after terminal differentiation
of cone and rod photoreceptors has been initiated. Interest-
ingly, we have recently identified Mef2c as a target of the
nuclear receptor NR1D1 in the adult mouse retina,46 and
NR1D1 was able to activate the Mef2c proximal promoter in
293T-cell based transactivation assays to a similar extent than
NRL (P. Escher and Neena Haider, unpublished data). Given
that these studies have been performed in a heterologous cell
system, the physiological relevance needs to be ascertained.
However, these different experimental observations provided
circumstantial evidence that Mef2c is involved rod photorecep-
tor maintenance.
From a mechanistic point of view, it is important to remem-
ber that no consensus NRL binding sites have been identified in
the Mef2c proximal promoter, and that Mef2c, NRL, and other
Maf-box containing transcription factors might compete for the
same binding sites. This could also contribute to the under-
standing of previously reported conflicting results about regu-
lation of the Mef2c promoter by Mef2c, in conjunction with
E-box binding myogenin transcription factors.15,47
Despite the fact that Mef2c had primarily been reported
to be a transcriptional activator,12 it appeared to be a tran-
scriptional repressor on all retina-specific promoter frag-
ments tested so far. Interestingly, in the olfactory system,
another sensory system, Mef2c has been shown to be nec-
essary to repress the neuronal gonadotropin-releasing hor-
mone gene.48 With respect to repression of the Mef2c pro-
moter by Mef2c, a similar autoregulation, either repressing
or activating, had been shown for Mef2a.49 Reportedly,
conversion of Mef2c into a repressor can be mediated by
sumoylation.50,51
These data support the view that Mef2c is part of a Nrl-
dependent rod-specific transcriptional network, may act as a
transcriptional repressor of photoreceptor-specific genes and
may impact on the development and maintenance of photore-
ceptors.
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FIGURE 7. NRL activates the mouse Mef2c promoter. (A) Sequence of
the analyzed region of the mouse Mef2c proximal promoter, located
upstream of the first untranslated exon of Mef2c (bold, highlighted) and
containing a myocyte-specific enhancer conserved among vertebrates
(429/1). A/T-rich sequences (bold, underlined) and potential re-
sponse elements for c-Maf (bold, highlighted, underlined), Crx (italics),
Pax6 (underlined), Pax2 (highlighted), and an E-box motfif binding
MyoD (bold, highlighted) are indicated. (B) Schematic representation of
the Mef2c promoter constructs used in this study. On top, the nucleotide
numbering is indicated, with1 being the transcription start site. The first
exon is represented as a black box. A/T-rich regions (light gray triangle),
c-Maf binding site (black triangle), Pax6 binding site (oval), and E-box
(diamond) are indicated for clarity. (C) Deletion analysis of the Mef2c
promoter by transactivation assays in HEK293T cells. Nucleotide number-
ing of the Mef2c regions subcloned into the luciferase reporter constructs
are indicated at the bottom. Mouse Mef2c (M), human NRL (N), and
human CRX (C) expression vectors were cotransfected with the luciferase
reporter constructs (n  6–12). Firefly luciferase activities were nor-
malized to -galactosidase activities and presented as fold-induc-
tions relative to the 1141/170 promoter construct cotransfected
with the empty pcDNA3.1 expression vector (e).
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